The March 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule includes the following new/revised entries:

• Aripiprazole (Abilify Maintena) - new formulation
• Coal tar (Scytera) - new formulation
• Glucose indicator (Healthpro) - new formulation
• Glucose indicator (GluNeo) - new formulation
• Glucose indicator (Dario) - new formulation
• 6-mercaptopurine hydrochloride (Allmercap) - new formulation
• Peginterferon alfa-1a (Plegridy) - new medicine
• Anastrozole (Arimidex) - new indication
• Everolimus (Afinitor) - new indication
• Exemestane (Aromasin) - new indication
• Goserelin acetate (Zoladex) - new indication
• Letrozole (Femara) - new indication
• Ranibizumab (Lucentis) - restriction change
• Capecitabine (Xeloda) - restriction change
• Megestrol acetate (Megace) - restriction change
• Toremifene citrate (Fareston) - restriction change
• Vinorelbine tartrate (Navelbine) - restriction change

For more details, go to: http://www.pbs.gov.au/browse/changes